Neurocrine Biosciences
NBIX
#1490
Rank
A$20.72 B
Marketcap
A$203.85
Share price
0.84%
Change (1 day)
-4.69%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total liabilities

Total liabilities on the balance sheet as of June 2026 : A$2.38 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total liabilities are A$2.38 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Neurocrine Biosciences - Total liabilities on balance sheet (from 2001 to 2026)

Total liabilities by year

Year Total liabilities Change
2025-12-31A$2.05 B13.38%
2024-12-31A$1.81 B21.31%
2023-12-31A$1.49 B54.06%
2022-12-31A$0.97 B0.8%
2021-12-31A$0.96 B21.75%
2020-12-31A$0.79 B-17.19%
2019-12-31A$0.95 B31.39%
2018-12-31A$0.72 B27.47%
2017-12-31A$0.57 B719.15%
2016-12-31A$69.65 M0.82%
2015-12-31A$69.08 M64.68%
2014-12-31A$41.95 M9.21%
2013-12-31A$38.41 M-4.05%
2012-12-31A$40.03 M-47.56%
2011-12-31A$76.35 M-37.99%
2010-12-31A$0.12 B65.43%
2009-12-31A$74.43 M-35.49%
2008-12-31A$0.11 B-36.13%
2007-12-31A$0.18 B90%
2006-12-31A$95.09 M-25.2%
2005-12-31A$0.12 B-21.54%
2004-12-31A$0.16 B-26.49%
2003-12-31A$0.22 B193.68%
2002-12-31A$75.05 M6.53%
2001-12-31A$70.45 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
A$165.49 B 6,843.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$201.78 B 8,366.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$155.13 B 6,408.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.19 B-49.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A$62.71 M-97.37%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$1.28 B-46.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A$3.76 M-99.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$14.35 B 502.47%๐Ÿ‡ฌ๐Ÿ‡ง UK